Kornimate/medical-research-clean huggingface dataset:
the first-line combined chemotherapy for advanced gastric cancer: a prospective observational clinical study

Conditions: Gastric Cancer

Summary: this prospective cohort study aims to observe the efficacy and safety of the first-line combined chemotherapy for advanced gastric cancer(agc) in chinese population.

1. establish a clinical database for the advanced gastric cancer patients treated with first-line combined chemotherapy in tongji hospital. 1.1.data including age, gender, smoking state, karnofsky performance score（kps）, disease history, clinical stage, primary tumor site, metastasis site, surgery, first-line chemotherapy, therapy after failure of first-line treatment, radiotherapy, toxicity, survival time, the time of free of progress, response were collected. 1.2.the peripheral blood samples were collected for further biomarker reserch. 2. kaplan-meier and cox model will be used to analyze the overall survival(os) and progression-free survival(pfs) of advanced gastric cancer. 3. extract deoxyribonucleic acid（dna） from the the peripheral blood and research biomarkers related to the first-line combined chemotherapy for agc.

Eligibility criteria:
inclusion criteria: 1. histopathology or cytopathology proven gastric cancer or gastroesophageal adenocarcinoma; 2. unresectable locally advanced, or recurrent, or metastasis disease； 3. chemotherapy-naive or disease progress at least 6 months after adjuvant chemotherapy completed. 4. life expectancy of at least 3 months; 5. ecog score 0-2; 6. voluntarily signed the informed consent. exclusion criteria: 1. previously treated with first-line chemotherapy; 2. first-line chemotherapy with single drug.

Keywords: gastric cancer first-line chemotherapy biomarker
expanded access program for participants who completed study 13-601 and continue to clinically benefit from cerdulatinib

Conditions: Relapsed/Refractory Chronic Lymphocytic Leukemia; Non-hodgkin's Lymphoma

Summary: this expanded access program will provide continued access to cerdulatinib to eligible participants who experienced clinical benefit from cerdulatinib in study 13-601 (nct01994382) and who otherwise meet the eligibility criteria.


Eligibility criteria:
inclusion criteria: * participant has completed portola study 13-601 and wishes to continue treatment with cerdulatinib. * in the opinion of the investigator, the potential benefit to the participant of continuing to receive cerdulatinib outweighs the risks. * female participants of childbearing potential and male participants must agree to continue to abstain from sexual intercourse or to remain on an effective method of contraception during treatment and for 90 days following the last dose of protocol therapy (examples of effective methods of contraception include oral contraceptives or double barrier methods, such as condom plus spermicide or condom plus diaphragm). * participant must be willing to give written informed consent and be able to adhere to dose and visit schedules. exclusion criteria: * participant requires chronic treatment with a strong cyp3a4 inhibitor or inducer. * participant has a known hypersensitivity to any of the components of cerdulatinib. * participant is female and is breast-feeding, pregnant, or intends to become pregnant. * participant is participating in any therapeutic clinical study.
orthognathic surgeries and pharyngeal airway space

Conditions: Mandibular Prognathism

Summary: twenty-four patients with dentoskeletal deformity of class iii will be divided equally into two groups and will be subjected to orthognathic surgeries group a; will be treated by mandibular setback surgery while group b will be treated with bimaxillary orthognathic surgery in the form of mandibular setback and maxillary advancement surgeries. the total pharyngeal airway will be measured on lateral cephalometric radiographs, integrating retro-palatal and retro-glossal area, and statistically will be compared preoperative, immediate postoperative, and at 6 months post-surgically


Eligibility criteria:
inclusion criteria: * dento-skeletal class iii malocclusion which needed a surgical intervention with maxillary advancement surgery and/or mandibular set-back orthognathic surgery in the form of bilateral sagittal split osteotomy * no previous orthognathic surgery exclusion criteria: * patients with craniofacial syndromes. * medically compromised patients and patients with bone anomalies

Keywords: orthognathic surgery pharyngeal airway space skeletal class iii patients.
combination diagnostic strategies in nafld

Conditions: Non-Alcoholic Fatty Liver Disease; Chronic Liver Disease

Summary: serial combination of biological and elastography tests is accurate to diagnosing advanced fibrosis in non-alcoholic fatty liver disease (nafld) patients. in this study, the investigators compared the diagnostic performances of a 2-step strategy using either vibration-controlled transient elastography (vcte) or bidimensional shear wave elastography with supersonic imagine (2d-swe-ssi), and analysed the added-value of a 3-step strategy.

the investigators retrospectively selected all consecutive adult patients with suspicion of nafld who had undergone liver biopsy from november 2011 to july 2019 in 2 french academic centers, angers and bordeaux university hospitals. a total of 577 patients were included. among them, 291 had been previously included in a prospective study comparing diagnostic performances of several non-invasive tests in nafld patients. inclusion criteria were: age≥18yo, 2d-swe-ssi and vcte performed within the two weeks prior to liver biopsy. exclusion criteria were high alcohol consumption (i.e., \>21 drinks, on average, per week in men and \>14 drinks, on average, per week in women), associated causes of liver disease (alcoholic, viral, or other causes of liver injury), other aetiologies than nafld on pathological examination, and a liver biopsy length of less than 10 mm and/or fewer than 6 portal spaces and/or more than 2 fragments, except for in cases of cirrhosis.

Eligibility criteria:
inclusion criteria: - patients who underwent a liver biopsy for a suspicion of nafld, and liver stiffness evaluation with either fiborscan and bidimensional shear wave elastography exclusion criteria: * other aetiologies of chronic liver disease * biopsy length under 10mm

Keywords: liver elastography liver fibrosis non-invasive diagnosis nafld
open-label extension study to assess glm101 in pmm2-cdg patients

Conditions: Pmm2-CDG; Phosphomannomutase 2 Deficiency

Summary: the goal of this clinical trial is to provide continued access to glm101 to treat pmm2-cdg in people who have previously received glm101 in other trials. it will also learn about the long term safety of glm101. participants will complete weekly infusions of glm101 at the same dose level received in previous trials.

this is a phase 2 open-label clinical study of glm101 in patients with pmm2-cdg who have previously participated in a study of glm101. this study is designed to monitor long-term safety and treatment effect of glm101 and provided continued access to study treatment. participants will continue weekly infusions of glm101 at the same dose level they received in the previous study. dose levels may be adjusted to lower doses or higher doses based on available data that demonstrates a change to be safe and tolerable. participants will be asked to complete questionnaires to evaluate changes in ataxia and quality of life.

Eligibility criteria:
inclusion criteria: * willing and able to provide informed consent/assent and/or their legally authorized representative * completed previous clinical study with glm101 * if female of childbearing potential, must not be pregnant and use a medically accepted method of contraception * if male and sexually active must agree to use a medically acceptable method of contraception * willing ad able to adhere to study requirements described in the protocol exclusion criteria: * has a condition that would compromise safety or compliance of participant or preclude participant completion of study * has positive serum pregnancy test * unwilling or unable to comply with scheduled visits, study drug administration plan, laboratory tests, other study procedures, and study restrictions.

Keywords: glm101 pmm2 cdg cdg 1a
ketorolac in breast cancer surgery

Conditions: Curative Breast Cancer Surgery; Inflammatory Positive/Negative Status; Pre Surgical Incision Administration

Summary: do the use of ketorolac in one intravenous injection at the moment of the operative incision reduce the number of recurrence in patient with advanced breast cancer without inflammation signs.


Eligibility criteria:
inclusion criteria: written informed consent age : 18-85 years weight: 50-100 kg neutrophils / lymphocytes ratio \>4 and/or "triple negative" histological status and/or positive lymph nodes exclusion criteria: previous cancer (behalf of basocellular skin cancer and in situ uterine cervix cancer) non compliance or refusal of the protocol positive pregnancy test childbearing or breastfeeding mothers contra-indication for nsaids nsaids intake in the 5 days before randomisation nsaids use planned in the 30 days after randomisation non curative surgery (t4 or m1 tumor classification )
teach-back method on quality of life in heart failure patients

Conditions: Heart Failure

Summary: this study determines effect of education with teach-back method in patients with heart failure. in this randomized clinical trial, 70 patients with heart failure hospitalized in year 2016-17 were selected and they were randomly divided into control group and test group.self-care behaviors training with teach-back method within 15 to 45 minutes was done on the case group, and control group received routine treatment. information have collected whit demographic questionnaire and sf36 questionnaire before and after training. data were analyzed by spss version18 and there were analyzed by descriptive statistics and chi-square, independent t-test, paired t-test and co-variance tests.


Eligibility criteria:
inclusion criteria: * age from 45 to 85 * heart failure diagnosed six months ago * the ejection fraction less than 45 * have reading and writing skills * have perfect consciousness * fluency in persian exclusion criteria: * patient do not cooperate with researchers * the inability of each sample to continue cooperation during the study because of the problem or acute disease.

Keywords: self care heart failure quality of life teach-back
suction on post-operative chest tubes

Conditions: Non-small Cell Lung Cancer

Summary: the level of suction on post-operative chest tubes after video-assisted thoracoscopic surgery (vats) lobectomy for lung cancer has previously shown to affect duration of drainage. these results, however, are based on traditional drainage systems with water seal and need to be confirmed using digital drainage systems. hypothesis: suction of -2 cmh2o is equal to or superior compared with standard suction of -10 cmh2o when looking at chest tube duration and complications.


Eligibility criteria:
inclusion criteria: * speaks and understands danish. * referred for planned vats lobectomy for confirmed or suspected primary lung cancer. exclusion criteria: * cannot cooperate or unable to give consent. * chronic drain carrier. * planned open procedure. * planned resection of additional wedge, additional lobe or thoracic wall.
impact of the boost gait program on gait recovery and functional mobility after stroke

Conditions: Stroke with Hemiparesis; Stroke

Summary: the overarching goal is to determine if the boost gait program can improve functional mobility in patients with stroke who are undergoing inpatient rehabilitation and have some walking function, through the application of augmented therapeutic exercises designed to achieve a normative gait pattern. the evaluation will be conducted using a combination of clinical scales and objective motion sensors that map walking quality and performance during activities of daily living, such as rising from a chair and standing. it is acknowledged that this single-group pilot study, which aims to include 12 participants, is insufficiently powered to address the primary objective. a larger parallel-design study is required to definitively address this issue. to help design a larger study, the current objectives are: first, to have realistic expectations regarding recruitment and dropout rates; second, to identify potential barriers to therapy adherence and data collection that may impede the success of a larger study; third, assess the test-retest reliability of sensor-based motion capture of movement quality during walking and related tasks in hemiparetic stroke patients. for the latter objective, the sensor measurements at the end of the intervention will be repeated on two consecutive days. in addition to their usual care, participants will undergo additional therapy over a four-week period, with sessions occurring five times per week for one hour as part of the boost gait program. the boost gait sessions will be conducted as group-based therapy with four patients and two physiotherapists present to oversee the performance of mobility-specific exercises, including sit-to-stand transfers, standing and stepping, and eventually walking. the rationale for this approach is that the combined effects of augmenting the amount of therapeutic exercises and specifically targeting motor control of the paretic leg will facilitate symmetry during tasks, which in turn will have carry-over effects on safe performance of walking and other mobility tasks.


Eligibility criteria:
inclusion criteria: * a first-ever unilateral stroke, infarction or bleeding * undergoing inpatient rehabilitation in the jessa hospital, herk-de-stad * less than 3 months after stroke onset at the moment of inclusion * 18 years of older * berg balance scale score 24 or higher (out of 56) at moment of inclusion * timed up-and-go score 14 s or higher at moment of inclusion * functional ambulation category 3 or higher at moment of inclusion * understanding the goals and procedures of this study and giving informed consent exclusion criteria: * significant cognitive and/or speech impairments that markedly affect the comprehension and execution of instructions

Keywords: recovery gait physical exercise pilot study stroke hemiparesis walking
prognostic value of pd-l1 in nsclc

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: this is an observational retrospective study. the primary objective is to investigate the expression and potential prognostic role of programmed death ligand 1 (pd-l1) in tumor samples from 350 patients with early stage treatment-naive non-small-cell lung cancer (nsclc). tissue samples were embedded in a tissue microarray. pd-l1 will be studied by immunohistochemistry using the sp263 antibody. stained samples will be evaluated independently by two operators. a tumor will be defined as positive when = or \>50% of tumor cells express the ligand. the investigators will investigate the relationship between pd-l1 protein expression and overall survival and other clinical characteristics with appropriate statistical methods.


Eligibility criteria:
inclusion criteria: * early stage treatment-naive nsclc exclusion criteria: * received any pre-surgical treatment * no os data available
shock waves for treatment of gynoid lipodystrophy and localized fat

Conditions: Lipodystrophy; Cellulitis; Adiposity

Summary: purpose: to evaluate the efficacy of shock waves extracorporea in improving body contour,decrease fat localized and appearance of gynoid lipodystrophy. subjects and methods: a prospective and comparative longitudinal clinical study will be performed in 30 women with localized fat and gynoid lipodystrophy. patients will be submitted data collection and assessments and before and after treatment. hypotheses: it is expected that the patients will present improvement in the body contour, decrease fat localized and in the picture of the gynoid lipodystrophy after of the therapies. statistical analysis: a descriptive analysis will be done before and after vibration-oscillatory therapy, with frequency tables for categorical and descriptive variables (mean, standard deviation, median, minimum and maximum values) for continuous or numerical variables. in order to compare the main variables between the groups and the collection times, the analysis of variance (anova) for repeated measurements will be used. tukey's test will be used to compare groups. the level of significance adopted for the statistical tests will be 5% or p \<0.05.

after signing the informed consent, the participants will be evaluated by two physiotherapists where the data collected will be personal data, anthropometrics and complementary diagnostic tests, such as: ultrasound diagnosis to evaluate the thickness of the adipose tissue and cutomiter analysis of the viscoelasticity of skin. they then started treatment with another physiotherapist who will perform the following study protocol: placing a light layer of neutral gel on the treatment area, applying extracorporeal shock waves with the stainless steel tip with 180mj of energy totaling 4 thousand shots , in abdomens, buttocks and posterior thigh and 2 thousand shots in flanks, then performs the change of the tip to the plastic and performs 2 thousand shots in the regions of abdomens, buttocks, posterior thigh emil shots in the region of flanks. the protocol will be performed twice a week for 1 and 20 hours each, totaling 10 sessions.

Eligibility criteria:
inclusion criteria: * women older than 18 years of age up to premenopausal age (50 years of age). * with body mass index considered eutrophic and / or overweight. * patients with lipodystrophy and localized abdominal fat. * non smokers. * who agree to participate and sign the informed consent form. exclusion criteria: * male gender. * possible. * haemophilia carriers and hemorrhagic disorders. * carriers diabetes mellitus. * women in menopause. * performed aesthetic treatment in the gluteal, thigh and abdominal regions in the last 1 months. * patients with skin lesions, such as dermatitis and dermatoses. * patients with acute deep vein thrombosis (dvt). * about or close to cancerous lesions. * patients with cardiac pacemaker or other implanted electronic device.

Keywords: shock wave gynoid lipodystrophy cellulits
persistent atrial fibrillation ablation and correlation to quality of life

Conditions: Atrial Fibrillation

Summary: the primary objective of this study is to determine the atrial fibrillation burden reduction, or absolute atrial fibrillation burden, associated with improvement in quality of life in patients undergoing ablation of persistent atrial fibrillation.

atrial fibrillation (af) is associated with a higher risk of stroke, heart failure and deterioration in patients' quality of life and it also has great effect on health care resource utilization due to increasing morbidity and mortality. catheter ablation has shown to improve patients' quality of life (qol), even in those who undergo a repeat procedure, equalizing healthy population and lowering subsequent health care resource utilization. success rates are usually based on an endpoint of total elimination of af, typically absence of any af recurrence \>30 seconds. while this is a high standard for clinical trial reporting, it does not necessarily measure the "clinical" success, since many patients will experience significant reduction in their af burden with accompanying improvement in their functional status despite having ongoing brief recurrences of af. this is a prospective non-randomized, single-arm, cohort study. 200 patients with persistent atrial fibrillation undergoing catheter ablation will be enroled. af burden post procedure will be evaluated with continuous monitoring with an implantable loop recorder (ilr) to assess recurrences and af burden. qol will be measured using the ccs-saf severity scale, sf-36 and afeqt scales pre-ablation and at 12 and 24 months.

Eligibility criteria:
inclusion criteria: * age \> 18 years * patients undergoing first-time or redo af ablation. * persistent or long-standing persistent af * symptomatic atrial fibrillation * willing and able to provide informed consent. * willing and able to set up and utilize mycarelink® home monitor and be remotely monitored * atrial fibrillation burden equal or more than 80% prior to the ablation exclusion criteria: * paroxysmal af * if the patient has had a cardioversion within 2 months of the ablation * patients with contraindication to oral or intravenous anticoagulation. * contraindication to implantation of an ilr

Keywords: catheter ablation quality of life atrial fibrillation burden persistent atrial fibrillation
type 2 diabetes treatment and remission with a very low-calorie ketogenic diet (vlckd) and lifestyle changes

Conditions: Type 2 Diabetes Mellitus; Overweight and Obesity

Summary: there is a strong correlation between being overweight, specifically with abdominal fat, and type 2 diabetes mellitus (t2dm). recent scientific literature has highlighted the connection between significant weight loss, specifically 15% or more of body weight, and its positive impact on body composition and glycemic profiles. in this study, the focus is on very low carbohydrate ketogenic diets (vlckds) as a nutritional strategy for managing excess weight and improving diabetes. current research is transforming the understanding of t2dm, demonstrating that effective and timely interventions can lead to diabetes remission, including a partial recovery of insulin secretion and function. however, the daily life of a diabetic patient in a clinical setting may not always mirror that of a patient participating in a study, who receives planned follow-up visits and close supervision. to address this discrepancy, this study aims to analyze a cohort of patient records with t2dm and overweight who have adopted a vlckd, specifically through the pnk® method, in a private diabetology practice. the goal is to assess the impact of vlckd on glycemic control in real-life scenarios.

the investigator wishes to carry out an observational, retrospective, uncontrolled, monocentric analysis on a group of patients with overweight and type 2 diabetes mellitus (t2dm). the analysis will focus on the observation of the evolution of anthropometric and clinical parameters, such as the improvement or normalization of hba1c, as well as on the evolution of the hypoglycemic medication. the data collected and analyzed will correspond to 4 moments: 1. t0, at the start of treatment. 2. t1, at the end of vlckd, period of ketosis with an average duration of 12 weeks. 3. t2, after 6-9 months of support and individualized therapeutic education for a new lifestyle. 4. t3, after 18-24 months of usual follow-up with 1 visit every 3 to 6 months. the population included in the analysis consists of adults with t2dm, with a bmi greater than 25 kg/m2, followed in a diabetology office. this constitutes a form of selection of the population because people with more social, economic, linguistic difficulties, more complex pathologies will be better taken care of in a hospital environment.

Eligibility criteria:
inclusion criteria: * have a diagnosis of type 2 diabetes * being overweight (bmi \> 25 kg/m\^2) or obesity (bmi \> 29.9 kg/m\^2) * have wished to engage in a weight loss program according to the pnk® method * have accepted and signed the consent for the use of data exclusion criteria: * pregnancy or lactation * type 1 diabetes * eating disorders * psychiatric disorders * have any contraindication for doing the active or ketogenic phase

Keywords: very low-calorie ketogenic diet vlckd type 2 diabetes overweight obesity